. 2021 Jul 13;19:211. doi: 10.1186/s12957-021-02326-y

Table 2.

Relationships between central lymph node metastasis mutation and clinicopathologic characteristics of 943 patients with PTC

Variable	Overall PTC(n = 943)					PTC > 10 mm(n = 373)					PTMC(n = 570)
	Yes	No	Uni- and multivariate analysis			Yes	No	Uni- and multivariate analysis			Yes	No	Uni- and multivariate analysis
	n(%)	n(%)	P	P	OR(95CI)	n(%)	n(%)	P	P	OR(95CI)	n(%)	n(%)	P	P	OR(95CI)
Gender
Male	166(71)	67(29)	< 0.001	< 0.001	0.41 (0.28–0.58)	90(84)	17(16)	0.004	0.02	0.48 (0.26–0.88)	76(60)	50(40)	< 0.001	< 0.001	0.37 (0.24–0.57)
Female	339(48)	371(52)	< 0.001	< 0.001	0.41 (0.28–0.58)	185(70)	81(30)	0.004	0.02	0.48 (0.26–0.88)	154(35)	290(65)	< 0.001	< 0.001	0.37 (0.24–0.57)
Age (years) ^*	43.6 ± 12.2	47.2 ± 9.8	< 0.001	< 0.001	0.97 (0.96–0.98)	43.4 ± 12.6	49.2 ± 9.1	< 0.001	< 0.001	0.96 (0.94–0.98)	43.9 ± 11.7	46.6 ± 10.0	0.001	0.01	0.98 (0.96–0.99)
Tumor size (mm)^*	1.5 ± 1.1	0.9 ± 0.7	< 0.001	< 0.001	3.45 (2.48–4.79)	2.1 ± 0.8	1.8 ± 0.8	0.01	0.02	1.49 (1.08–2.06)	0.7 ± 0.2	0.6 ± 0.2	0.002	0.002	3.65 (1.62–8.21)
Focality
Uni	355(52)	333(48)	0.055			186(72)	73(28)	0.206			169(39)	260(61)	0.417
Multi	150(59)	105(41)	0.055			89(78)	25(22)	0.206			61(43)	80(57)	0.417
HT
No	491(55)	402(45)	< 0.001	0.03	0.42 (0.19–0.91)	270(75)	88(25)	< 0.001	0.006	0.21 (0.07–0.64)	221(41)	314(59)	0.068
Yes	14(28)	36(72)	< 0.001	0.03	0.42 (0.19–0.91)	5(33)	10(67)	< 0.001	0.006	0.21 (0.07–0.64)	9(26)	26(74)	0.068
T staging
T1	418(50)	420(50)	< 0.001	< 0.001	4.94 (2.84–8.59)	188(70)	80(30)	0.01	0.723		230(40)	340(60)	–
T2 + T3	87(83)	18(17)	< 0.001	< 0.001	4.94 (2.84–8.59)	87(83)	18(17)	0.01	0.723		0	0	–
BRAF^V600E mutation
No	75(62)	62(38)	0.742			51(82)	11(17)	0.095			25(40)	50(60)	0.121
Yes	430(36)	376(64)	0.742			224(72)	87(28)	0.095			205(41)	290(59)	0.121

Abbreviations: PTC papillary thyroid carcinoma, PTMC papillary thyroid microcarcinoma, HT Hashimoto’s thyroiditis, CLNM central lymph node metastasis

*Numbers are presented as means ± standard deviation